AVLN is Avalyn Pharma Inc. (Healthcare) — a non-dividend-paying stock. Trading at $37.39. Market cap: $1.66B.
Stock snapshot
| Price | $37.39 |
| Market cap | $1.66B |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
About AVLN
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Related non-dividend companies
Other non-dividend stocks investors research alongside AVLN. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is AVLN's current stock price?
AVLN (Avalyn Pharma Inc.) is currently trading at $37.39.
Does AVLN pay a dividend?
AVLN (Avalyn Pharma Inc.) does not currently pay a regular dividend.
Track AVLN in DiviDrip
Add AVLN to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search AVLN and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-07. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.